|
|
Article: ESTORRA(TM) Six-Week Phase III Study Presented At Associated Professional Sleep Societies Meeting.
- Article from:
- PR Newswire
- Article date:
- June 9, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Sepracor Inc. today announced the presentation of data from a pivotal six-week, placebo-controlled Phase III clinical trial conducted with ESTORRA(TM) brand eszopiclone at the annual meeting of the Associated Professional Sleep Societies (APSS) in Chicago.
Results of the large-scale, randomized, double-blind, multicenter, placebo-controlled, parallel-design study in adult patients 21-64 years of age, were presented by Gary Zammit, Ph.D., of the Sleep Disorders Institute at St. Luke's/Roosevelt Hospital in New York. This study was designed to investigate safety and efficacy of eszopiclone following nightly dosing over a period of six weeks and to assess the ...